金振口服液治疗儿童急性支气管炎的疗效、安全性与机制:随机双盲多中心临床试验方案
本研究为随机双盲平行对照多中心临床试验方案,计划纳入1000例儿童急性支气管炎患者,干预组予金振口服液加盐酸氨溴索盐酸克仑特罗口服溶液安慰剂,对照组反之,疗程7天,主要结局为咳嗽消失时间,并同步开展粪便和唾液宏基因组学与代谢组学分析探讨机制。
要点
- 金振口服液治疗儿童急性支气管炎的疗效与安全性尚需大样本随机双盲头对头研究验证。
- 该方案以咳嗽消失时间为主要结局,计划纳入1000例,由10家医院招募。
- 研究同步开展粪便和唾液宏基因组学与代谢组学分析,探索金振口服液作用机制。
核心结论
- 方案假设急性支气管炎患儿可从金振口服液治疗中获益,旨在评估其疗效、安全性与机制。
研究设计与样本
- 随机、双盲、平行对照多中心临床试验方案,干预组与对照组各500例,共1000例,由10家医院招募。
- 干预组予金振口服液加盐酸氨溴索盐酸克仑特罗口服溶液安慰剂,对照组予盐酸氨溴索盐酸克仑特罗口服溶液加金振口服液安慰剂,疗程7天。
- 两药剂量按年龄和体重调整,主要结局为咳嗽消失时间,采用SAS进行意向性分析,双侧检验,p<0.05为差异有统计学意义。
临床怎么用
- 该方案为儿童急性支气管炎的中成药治疗提供随机双盲多中心证据设计参考。
- 方案纳入机制研究(粪便和唾液宏基因组学与代谢组学),有助于阐释金振口服液抗急性支气管炎的作用途径。
局限性
- 本文为试验方案,尚未报告金振口服液治疗儿童急性支气管炎的疗效与安全性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Acute bronchitis (AB) is a common disease in pediatrics. Prolonged AB may develop into chronic bronchitis. Bronchitis caused by the influenza virus can lead to severe hypoxia or insufficient ventilation, causing great harm to patients and increasing the burden on children and society. Presently, there is no specific treatment for AB except symptomatic supportive treatment. It is urgent to find an effective treatment for AB. Jinzhen Oral Liquid (JZOL) has been found to have a broad spectrum of anti-inflammatory and antiviral effects in previous clinical and basic studies and has a good effect on AB in children. However, the large-sample, randomized, double-blind, head-to-head, evidence-based studies are lacking. The purpose of this protocol is to evaluate the efficacy, safety, and mechanism of JZOL in the treatment of AB in children. Methods: This is a randomized, double-blind, parallel-controlled multi-center clinical trial. The sample size is 500 participants in the intervention group and the control group respectively, with a total of 1000 participants. They will be recruited by 10 hospitals in China. The Intervention group takes JZOL and Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution (AHCHOS) placebo, while the control group receives AHCHOS and JZOL placebo. The dosage of the two drugs varies according to age and weight. The medication lasts for 7 days. The disappearance time of cough is adopted as the primary outcome. Quality control will be carried out at every stage of data management and processing to ensure that all data are reliable and processed correctly. SAS is used for statistical analysis. Intention-to-treat analysis will be carried out in this trial. All statistical tests are conducted using a two-sided test, and p <0.05 would be considered statistically significant. Discussion: We hypothesized that children with AB could get good health benefits from JZOL. This study not only evaluates the clinical efficacy and safety of JZOL but also conducts metagenomics analysis and metabolomics analysis of feces and saliva of participants to study the mechanism of JZOL against AB. Therefore, this protocol evaluates the efficacy, safety, and mechanism of JZOL from a comprehensive perspective, so as to obtain a more solid evidence chain, which will enhance the credibility of the evidence. If successful, this study will provide a high-level evidence-based reference for the treatment of AB in children and future relevant studies.
引用
- Cui X, Liang L, Geng H, et al. Efficacy, Safety and Mechanism of Jinzhen Oral Liquid in the Treatment of Acute Bronchitis in Children: A Randomized, Double-Blind, Multicenter Clinical Trial Protocol. Front Pharmacol. 2022. PMID: 35847029. doi:10.3389/fphar.2022.948236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。